Endologix Acknowledges Receipt of Unsolicited Offer from Elliot Associates
October 15 2008 - 4:37PM
Business Wire
Endologix, Inc. (Nasdaq:ELGX), developer of the Powerlink� System
for the minimally invasive treatment of abdominal aortic aneurysms
(AAA), today acknowledged receipt of an unsolicited proposal from
Elliott Associates, L.P. to purchase all of the outstanding shares
of Endologix for $2.25 per share. Consistent with its fiduciary
duties and in consultation with its financial advisors and legal
counsel, Endologix Board of Directors will review and consider the
unsolicited proposal and will make a determination and respond in
due course. Endologix urges its stockholders to defer judgment on
the unsolicited proposal until that determination has been made.
About Endologix Endologix, Inc. develops and manufactures minimally
invasive treatments for vascular diseases. Endologix Powerlink
System is an endovascular stent graft for treating abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the aorta, the
largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and, if
left untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is approximately
75%, making it a leading cause of death in the U.S. Additional
information can be found on Endologix website at www.endologix.com.
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jul 2023 to Jul 2024